Hims vs Fella Health: Program Models and Medication Overview

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — evidence-based guidance on GLP-1 therapies, weight management protocols, and the genetic factors behind every metabolic decision. Browse all Peptides & GLP-1 education.

Comparing two subscription-era telehealth models

Anyone weighing Hims against Fella Health is really comparing two brand experiences layered on top of the same drug classes. Both belong to a GLP-1 telehealth market that, by April 2026, spans dozens of near-equivalent services. This overview walks the program models side by side and leaves the buying decision to you and your clinician.

Editorial independence statement: PlexusDx holds no partnership, affiliate link, or paid arrangement with Hims or Fella Health. This overview is unsponsored.

The Hims model at a glance

Hims (Hims & Hers Health) runs a broad subscription-telehealth platform. In weight management that typically means a virtual clinical evaluation, a provider-issued prescription, and either brand-name FDA-approved GLP-1 dispensing or a compounded semaglutide/tirzepatide route through licensed compounding-pharmacy pathways. The current program layout is on Hims's official website.

The Fella Health model at a glance

Fella Health positions itself as men-focused telehealth. Its plan tiers, medication choices, and provider structure evolve, so the current details belong on Fella Health's official website. The structural contrast is mostly one of audience and packaging — a general-consumer platform versus a men-specific one — rather than a difference in the underlying pharmacology.

Where the two models actually diverge

Audience and onboarding

Hims casts a wide net across many health categories, while Fella Health narrows its messaging to men. That shapes marketing and intake tone more than clinical substance. Both still gate a prescription behind a licensed provider's review of your intake.

Dispensing pathway

Each can land on brand-name FDA-approved products or compounded alternatives depending on eligibility and availability. The compound class — GLP-1 receptor agonists like semaglutide, liraglutide, and dulaglutide, or the GIP/GLP-1 dual agonist tirzepatide — is what governs the biology.

What the trials say about the shared drug classes

Because the platform does not change the molecule, the evidence lives with the compounds. STEP examined semaglutide for weight management (NEJM 2021); SURMOUNT examined tirzepatide (NEJM 2022); SURMOUNT-OSA studied tirzepatide in obstructive sleep apnea (NEJM 2024). Results vary by dose, compound, and individual, which is why brand choice rarely decides outcome on its own.

Pricing: check each brand's page

Total monthly spend across GLP-1 telehealth programs varies widely as of April 2026 — roughly $200 to $700 or more once program fees, medication, and any compounded dispensing are included. Both Hims and Fella Health publish current numbers on their own sites, and those figures shift, so verify directly rather than trusting a secondhand quote.

The genetic variable no subscription includes

Neither model looks upstream at the genetics shaping your metabolic baseline. Variants in MC4R (central to satiety and energy balance), GLP1R (the GLP-1 receptor target), FTO, and TCF7L2 sketch the terrain any GLP-1 compound acts within — pathway-level context, not a prediction of drug response. PlexusDx offers semaglutide and tirzepatide via its Weight Management Protocols, and its Precision Peptide Genetic Test reads 14 pathways, 49 peptides, 150+ genetic insights so you and your provider start with more than a subscription form.

One practical takeaway: because both brands rest on the same molecules, the more useful comparison is not which name is stronger but which onboarding, provider access, and support cadence fits your situation. A platform's polish does not change the compound, and a men-specific brand does not alter the underlying dose response.

No affiliation: PlexusDx has no commercial relationship with Hims, Fella Health, or the other brands mentioned here.

Related reading on PlexusDx: GLP 1 Drugs, GLP 1 Hormone, What Is GLP 1, GLP 1 What Is.

Editorial disclaimer: This overview is educational and independent. PlexusDx sells semaglutide and tirzepatide through its own Weight Management Protocols and is not affiliated with Hims or Fella Health. The Precision Peptide Genetic Test shows how your genes influence peptide-related pathways — it does not predict response to any specific medication. Consult a licensed provider before starting a protocol.

Frequently Asked Questions

Is Hims or Fella Health a better fit for weight management?

Neither is universally better. Hims runs a broad subscription platform; Fella Health targets men specifically. The medication classes are the same, so fit comes down to onboarding, pricing tier, and provider access. Compare each brand's current program details before choosing.

Do Hims and Fella Health prescribe the same medications?

Both can prescribe GLP-1 receptor agonists and, where offered, GIP/GLP-1 dual agonists, through either brand-name or compounded pathways. The differences are in packaging and eligibility rules, not the underlying pharmacology, which is set by the compound rather than the telehealth brand delivering it.

How much do these programs cost per month?

Both publish pricing on their own sites, and figures change. Across the GLP-1 telehealth market as of April 2026, monthly totals commonly fall between roughly $200 and $700 or more depending on medication, tier, and dispensing route. Verify current rates directly before enrolling.

Will a genetic test show which brand suits me?

No. The Precision Peptide Genetic Test does not rank telehealth brands or forecast drug response. It maps pathway-level variants in genes like MC4R, FTO that describe your baseline metabolism — useful context regardless of which platform you eventually use.

Continue learning in the PlexusDx Education Hub. Browse all Peptides & GLP-1 education.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.